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Natural killer (NK) cells are immune innate effectors playing a pivotal role in the immu-
nosurveillance of multiple myeloma (MM) since they are able to directly recognize 
and kill MM cells. In this regard, among activating receptors expressed by NK cells, 
NKG2D represents an important receptor for the recognition of MM cells, being its 
ligands expressed by tumor cells, and being able to trigger NK cell cytotoxicity. The 
MHC class I-related molecule A (MICA) is one of the NKG2D ligands; it is encoded 
by highly polymorphic genes and exists as membrane-bound and soluble isoforms. 
Soluble MICA (sMICA) is overexpressed in the serum of MM patients, and its levels 
correlate with tumor progression. Interestingly, a methionine (Met) to valine (Val) 
substitution at position 129 of the α2 heavy chain domain classifies the MICA alleles 
into strong (MICA-129Met) and weak (MICA-129Val) binders to NKG2D receptor. 
We addressed whether the genetic polymorphisms in the MICA-129 alleles could 
affect MICA release during MM progression. The frequencies of Val/Val, Val/Met, and 
Met/Met MICA-129 genotypes in a cohort of 137 MM patients were 36, 43, and 22%, 
respectively. Interestingly, patients characterized by a Val/Val genotype exhibited the 
highest levels of sMICA in the sera. In addition, analysis of the frequencies of MICA-129 
genotypes among different MM disease states revealed that Val/Val patients had a 
significant higher frequency of relapse. Interestingly, NKG2D was downmodulated in 
NK cells derived from MICA-129Met/Met MM patients. Results obtained by structural 
modeling analysis suggested that the Met to Val dimorphism could affect the capacity 
of MICA to form an optimal template for NKG2D recognition. In conclusion, our findings 
indicate that the MICA-129Val/Val variant is associated with significantly higher levels of 
sMICA and the progression of MM, strongly suggesting that the usage of soluble MICA 
as prognostic marker has to be definitely combined with the patient MICA genotype.
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inTrODUcTiOn
Natural killer (NK) cells represent innate immune effectors 
playing a pivotal role in tumor surveillance. NK cell activation is 
regulated by a delicate balance between activating and inhibitory 
signals, with the latter being primarily transduced by receptors 
for MHC class I molecules (KIRs, CD94/NKG2A). Recognition of 
abnormal self on tumor cells triggers a number of non-MHC class 
I-restricted activating receptors, such as NK group 2D (NKG2D), 
DNAX accessory molecule-1 (CD226), and the natural cytotoxic-
ity receptors (1).
NKG2D is an activating receptor expressed on the surface of 
NK  cells, CD8+ T  cells, and subsets of CD4+ T  cells, invariant 
NKT  cells (iNKT), and γδ T  cells (1). NKG2D recognizes two 
families of ligands in humans: the MHC class I chain-related 
protein A/B (MICA/B) and the UL16-binding proteins (ULBP1-
6) (1). In general, healthy adult tissues do not express NKG2D 
ligands on the cell surface, but the expression levels of these 
molecules can be significantly induced by various physiological 
and pathological “stress” circumstances, including infection 
by different pathogens (1), cell division (2), and neoplastic 
transformation (3). Among all known NKG2D ligands, MICA 
is the most polymorphic non classical class I gene, with 104 
alleles identified to date (http://www.ebi.ac.uk/imgt/hla/, release 
3.25.0). Some MICA polymorphisms have raised a great interest 
since they can affect MICA biology. For instance, the MICA*008 
allele (rs67841474) contains a guanine (G) insertion that causes 
a premature stop codon that, in turn, crops 10 amino acids of 
the transmembrane domain as well as the cytoplasmic tail. In 
contrast to other MICA alleles that are shed as truncated soluble 
species after metalloproteinase-mediated cleavage, it is released 
from cells associated to exosomes (4). In addition, the single-
nucleotide polymorphism causing a valine (Val) to methionine 
(Met) modification at position 129 of the α2 heavy chain domain 
classifies these MICA alleles into high-affinity (MICA-129Met) 
and low-affinity (MICA-129Val) binders to NKG2D receptor 
(5). It has also been recently reported that MICA-129Met, 
characterized by stronger and faster NKG2D signaling, is able 
to trigger relatively higher NK cell cytotoxicity and IFNγ release 
accompanied by rapid downregulation of NKG2D (6). Significant 
differences in binding affinities of MICA alleles for NKG2D could 
have different effects on NK cell activation, in particular under 
conditions of suboptimal MICA expression.
Multiple myeloma (MM) is a clonal B cell malignancy charac-
terized by the expansion of plasma cells (PCs) in the bone marrow 
(BM) and is still an incurable disease with a median survival of few 
years. Its prognosis has been improved by the use of autologous 
hematopoietic stem cell transplantation (7) and new immuno-
chemotherapeutic approaches (8–10). NK cells play a pivotal role 
in MM immunosurveillance by exerting direct cytotoxic effects 
through a number of activating receptors, including NKG2D 
(11, 12). However, several mechanisms have been identified that 
permit the escape of tumors bearing NKG2D ligands, including 
their release by tumor cells through proteolytic cleavage (13–17) 
or exosome secretion (4). Furthermore, it has been demonstrated 
that MICA is transferred to NK  cells upon target conjugation 
and that this transfer is directly linked to molecular interactions 
between NKG2D and MICA, following accumulation of the 
ligand at the immunological synapse (18). Soluble MICA has 
been identified as an independent prognostic factor for the 
overall survival and progression-free survival of MM patients 
(19). In addition, endogenous anti-MICA antibodies and ligand 
shedding are critical determinants of host immunity during MM 
progression (20). It is, however, unknown whether functionally 
relevant polymorphisms of the MICA gene may also contribute 
to disease progression.
The aim of this study was to investigate the association of 
MICA genetic polymorphisms and MICA sera levels with 
progression of MM. Interestingly, our findings indicate that 
the MICA-129Met/Val dimorphism is associated with: (i) dif-
ferential expression of both soluble and cell-surface MICA, 
(ii) expression levels of NKG2D on ex vivo NK  cells isolated 
from the BM and peripheral blood (PBL) of MM patients, and 
(iii) the disease state.
resUlTs
MICA-129Val allele is associated  
With higher amount of soluble Mica  
in the sera of MM Patients
Soluble MICA has been proposed as a prognostic marker in 
MM since its levels correlate with tumor progression (19). 
However, the generation of soluble MICA can be affected by 
polymorphisms, regulating cell-surface expression, altering 
the efficacy of cleavage, and favoring MICA recruitment into 
exosome-like vesicles (4, 16, 21, 22). At first, we investigated 
whether soluble NKG2D ligands other than MICA in the 
sera derived from a cohort of MM patients at different disease 
states, namely MGUS (monoclonal gammopathy of unde-
termined significance), smoldering, onset, and relapse, were 
associated with MM progression. As shown in Figure  1A, 
we established that only soluble MICA but not other soluble 
NKG2D ligands including MICB and ULBP1-3 (data not 
shown) were associated to MM progression. Since we con-
firmed the importance of soluble MICA, we further explored 
whether MICA polymorphism could affect the amount of 
soluble MICA as well as MM progression. Therefore, MICA 
genotype was examined by isolating PBMCs DNA from a cohort 
of 137 MM patients at different disease states (Figure S1A in 
Supplementary Material). We also identified the sequence 
of a new MICA allele and the name MICA*085 has been 
officially assigned by the WHO Nomenclature Committee for 
factors of the HLA System. MICA alleles were further clas-
sified in three subgroups, MICA-129Val/Val, MICA-129Val/
Met, and MICA-129Met/Met (Tables  1 and 2). Similarly to 
other studies (6, 23–25), the frequencies of MICA-129Val/Val, 
MICA-129Val/Met, and MICA-129Met/Met genotypes were 
36, 42, and 22%, respectively (Figure S1B in Supplementary 
Material). Remarkably, the analysis of MICA-129 genotype 
frequencies among different MM states revealed that MICA-
129Val/Val patients displayed a significantly higher percent-
age of relapse (Figure  1B; Figure S1C in Supplementary 
Material). In contrast, the frequencies of MICA-129Val/Met 
FigUre 1 | MICA-129Val allele is associated with higher amount of sMICA in the sera of multiple myeloma (MM) patients. (a) Sera derived from healthy donors, 
MGUS, and MM patients at different state disease were analyzed for the presence of soluble MICA through a specific enzyme-linked immunosorbent assay. Total 
number of patients, 97 (healthy, n = 5, MGUS, n = 16, smoldering, n = 22, onset, n = 26, relapse, n = 32). (B) Frequency distribution of MICA-129 genotypes 
among different MM disease states. χ2 test with n − 1 degrees of freedom was performed. (c,D) sMICA is associated with the presence of the MICA-129 valine  
(Val) allele in MM patients. Total number of patients analyzed, n = 91 (Val/Val, n = 37; Val/Met, n = 36; Met/Met, n = 18).
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and MICA-129Met/Met genotypes were similar throughout 
all the different disease states (Figure 1B). Interestingly, MM 
patients characterized by the MICA-129Val/Val genotype 
also exhibited the highest levels of soluble MICA in the sera 
(Figure 1C). Consequently, correlation of soluble MICA with 
MM progression was observed only in the presence of the 
MICA-129Val allele (Figure  1D). We further explored the 
outcome of patients in response to the therapy among different 
MICA-129 genotypes (Figures 2A–C). As shown in Figure 2A, 
a similar response to chemotherapy was observed among the 
three genotypes. Interestingly, we observed that the highest 
frequency of relapse was developed by MICA-129Val/Val 
patients also after chemotherapeutic treatment (Figure  2B) 
suggesting that MICA polymorphism impacts on MM relapse.
TaBle 2 | Patient characteristics.
Patients 
characteristics
Val/Val Val/Met Met/Met
Gender
Male 25 31 13
Female 24 26 18
Age mean (range) 70 (47–83) 65(41–83) 62 (41–87)
% of PCs
mean (range)
MGUS 3 (1–10)
Smoldering 16 
(5–38)
Onset 29 (11–45)
Relapse 27 (4–90)
MGUS 4 (1–9)
Smoldering 18 
(4–40)
Onset 36 (7–90)
Relapse 29 (5–58)
MGUS 3 (1–10)
Smoldering 26 
(13–58)
Onset 29 (2–52)
Relapse 33 (4–54)
PCs, plasma cells; Val, valine; Met, methionine.
TaBle 1 | MICA genotype and 129 polymorphism in patients at different disease state.
MgUs patients
Mica genotype-129 
polymorphism
smoldering patients
Mica genotype-129 
polymorphism
Onset patients
Mica genotype-129 
polymorphism
relapse patients
Mica genotype-129 
polymorphism
002:01/018:01 Met/Met 002:01/018:01 Met/Met 009:01/018:01 Val/Met 085/085 Val/Val
008:01/016 Val/Val 018:01/018:01 Met/Met 002:01/18:01 Met/Met 002:01/008:01 Met/Val
004/012:01 Val/Met 008:01/008:01 Val/Val 004/009:02 Val/Val 002:01/016 Met/Val
016/019 Val/Val 017/019 Met/Val 004/008:01 Val/Val 004/016 Val/Val
008:01/018:01 Val/Met 008:01/011 Val/Met 002:01/010:01 Met/Val 009:01/009:01 Val/Val
002:01/018:01 Met/Met 002:01/018:01 Met/Met 004/008:01 Val/Val 002:01/004 Met/Val
001/018:01 Met/Met 006/008:01 Val/Val 010:01/017 Val/Met 002:01/018:01 Met/Met
006/008:01 Val/Val 009:01/018:01 Val/Met 008:01/018 Val/Met 009:01/009:01 Val/Val
002:01/011 Met/Met 001/018:01 Met/Met 008:01/008:01 Val/Val 016/019 Val/Val
009:01/018:01 Val/Met 002:01/018:01 Met/Met 027/027 Val/Val 008:01/009:01 Val/Val
010:01/018:01 Val/Met 009:01/009:01 Val/Val 008:01/010:01 Val/Val 008:01/009:01 Val/Val
008:01/011 Val/Met 010:01/012:01 Val/Met 004/004 Val/Val 008:01/019 Val/Val
009:01/018:01 Val/Met 004/008:01 Val/Val 004/008:01 Val/Val 009:01/016 Val/Val
004/018:01 Met/Val 008.01/018:01 Val/Met 008:01/018:01 Val/Met 008:01/009:01 Val/Val
002:01/008:01 Val/Met 004/008:01 Val/Val 004/016 Val/Val 002:01/004 Met/Val
004/008:01 Val/Val 002:01/047 Met/Met 002:01/018:01 Met/Met 009:02/018:01 Val/Met
002:01/008:01 Met/Val 009:01/009:02 Val/Val 008:01/018:01 Val/Met 004/009:02 Val/Val
004/011 Val/Met 008:01/009:01 Val/Val 007:01/016 Met/Val 008:01/016 Val/Val
002:01/017 Met/Met 008:01/012:01 Val/Met 004/008:01 Val/Val 001:01/018 Met/Met
002:01/008:01 Met/Val 011/018:01 Met/Met 012:01/018 Met/Met 001/002:01 Met/Met
008:01/008:01 Val/Val 006/008:01 Val/Val 002:01/004 Met/Val 002:01/007:01 Met/Met
008:01/012:01 Val/Met 008:01/010:01 Val/Val 006/009:01 Val/Val 008:01/018:01 Val/Met
002:01/009:02 Met/Val 002:01/004 Met/Val 008:01/018:01 Val/Met 009:01/018:01 Val/Met
011/012:01 Met/Met 002:01/009:01 Met/Val 008:01/018:01 Val/Met 009:01/016 Val/Val
009:01/016 Val/Val 002:01/018:01 Met/Met 002:01/002:01 Met/Met 002:01/018:01 Met/Met
004/016 Val/Val 002:01/008:01 Met/Val 002:01/012:01 Met/Met 004/008:01 Val/Val
002:01/018:01 Met/Met 009:02/018:01 Val/Met 002:01/016 Met/Val 007:01/008:01 Met/Val
002:01/007:01 Met/Met 018:01/027 Met/Val 008:01/010:01 Val/Val
011/047 Met/Met 001/008:01 Met/Val 002:01/007:01 Met/Met
008:01/016 Val/Val 002:01/018:01 Met/Met 009:01/016 Val/Val
004/011 Val/Met 007:01/008:01 Met/Val 001/016 Met/Val
002:01/008:01 Met/Val 002:01/016 Met/Val
009:01/009:01 Val/Val 008:01/016 Val/Val
001/004 Met/Val 002:01/016 Met/Val
006/018:01 Val/Met 008:01/010:01 Val/Val
007:01/009:01 Met/Val 009:01/016 Val/Val
002:01/018:01 Met/Met 008:01/009:01 Val/Val
004/018:01 Val/Met 002:01/010:01 Met/Val
018:01/018:01 Met/Met
002:01/008:01 Met/Val
008:01/017 Val/Met
009:01/018:01 Val/Met
002:01/008:01 Met/Val
Val, valine; Met, methionine.
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We asked whether MICA cell-surface expression levels on 
primary malignant PCs isolated from patients could be related 
to the MICA genotype. As shown in Figures  3A–C, MICA 
expression on malignant PCs, was significantly higher in 
MICA-129Val/Val MM patients compared to MICA-129Met/
Met MM patients, thus suggesting that the increased amount 
of soluble MICA in the sera of MICA-129Val/Val patients 
could be related to an higher expression of this allelic variant. 
Finally, we further classified MICA alleles into MICA short 
and long, based on the presence of the truncated MICA*008 
allelic variant, but no differences regarding soluble MICA 
serum levels and the correlation with the disease state were 
found (data not shown).
FigUre 2 | Patient outcome related to MICA-129 genotype. (a) Response to therapeutic treatment of multiple myeloma (MM) patients (Onset and Relapse).  
VGPR, very good partial response; PR, partial response; SD, stable disease; PD, partial disease, CR, complete remission. (B) Frequency of relapse development  
in MM patients after chemotherapy. χ2 test, p = 0.0413. (c) Frequency of deceased patients in MM patients after chemotherapy. Total patients, n = 74; Val/Val, 
n = 26; Val/Met, n = 32; Met/Met, n = 16. Abbreviations: Val, valine; Met, methionine.
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MICA-129Met allele is associated With  
an increased nKg2D Downmodulation  
on nK cells isolated From Patients
We next investigated whether MICA-129 polymorphism was 
also associated with different levels of NKG2D expression in MM 
patients. To this aim, NKG2D expression levels on ex vivo NK cells 
isolated from either PBL or BM of MM patients were evaluated. 
Cells were stained with anti-human CD45, -CD56, -CD3, -CD138 
mAbs, along with mAbs specific for NKG2D and DNAM-1 
activating receptors. After CD138 (corresponding to PCs) gate 
exclusion, analysis was performed on CD45+CD56+CD3− total 
NK  cells. Interestingly, our results demonstrate that NKG2D 
was significantly reduced on NK  cells derived from MICA-
129Met/Met patients compared to both MICA-129Val/Val 
and MICA-129Val/Met patients (Figures  4A,B). Indeed, the 
MICA-129Met allele that has a higher affinity to NKG2D, is able 
to induce significantly stronger downmodulation of NKG2D in 
both NK and CD8 T lymphocytes (6). Importantly, the expres-
sion levels of DNAM-1, used as control, were similar among all 
three different genotypes (Figures 4A,B), indicating that NKG2D 
downmodulation is an event likely associated to MICA-129 dimor-
phism. Decreased NKG2D expression on MICA-129Met/Met 
patients was also observed on NK cell subsets expressing low and 
high levels of CD16 as shown in Figures S2A,B in Supplementary 
Material. These results suggest that NKG2D downmodulation 
in MM patients depends essentially on MICA genotype and it 
is not associated with soluble MICA levels. To further support 
this observation, sera containing different amounts of soluble 
MICA (derived from patients carrying at least one Val allele) were 
incubated with PBL derived from healthy donors and NKG2D 
expression was evaluated after 16 h by immunofluorescence and 
FACS analysis by gating on CD56+CD3− NK cells. As shown in 
Figure  5, we did not observe a significant correlation between 
the levels of soluble MICA and the extent of NKG2D reduction.
residue Met129 is essential for 
appropriate Positioning of the α2–1 helix 
for nKg2D recognition
Two crystal structures of MICA have been hitertho determined, 
one alone (26) and the other in complex with its receptor NKG2D 
FigUre 3 | MICA cell-surface expression on malignant plasma cells (PCs) resulted higher in MICA-129Val/Val patients. Total cells derived from the bone marrow 
(BM) of patients at different disease states were stained with isotypic cIg or anti-MICA together with anti-CD38 and anti-CD138 mAbs. (a) MICA expression was 
analyzed by gating CD38+/CD138+ cells. (B) Representative histograms of different patients are reported. Values indicated in each histogram represent the ratio 
between the MFI value of MICA divided by the MFI value of the isotypic cIg. Solid gray histogram: cIg; black line: MICA. (c) Total number of patients analyzed, 
n = 50 (Val/Val = 23, Val/Met n = 18, Met/Met = 9) that were smoldering (n = 10), onset (n = 19), and relapse (n = 21). Abbreviations: Val, valine; Met, methionine.
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(27). At first sight, MICA resembles classical MHC class I (MHC-
I) molecules with three extracellular domains (α1, α2, and α3), 
a transmembrane segment that can vary significantly between 
different MICA alleles, and a carboxy-terminal cytoplasmic 
tail. However, in contrast to MHC-I, MICA does not bind to 
the β2microglobulin and does not present peptides in the cleft. 
Comparison of the two structures revealed that the receptor-free 
form of MICA is disordered within a section of the α2 region 
FigUre 4 | MICA-129Met allele is associated with an increased NKG2D downmodulation on natural killer (NK) cells gated from patients. Total cells derived from the 
bone marrow (BM) or the peripheral blood (PBL) derived from patients at different disease states (including smoldering, onset, and relapse) were stained with antibodies 
against CD45, CD138, CD56, and CD3. NKG2D or DNAM-1 expression was evaluated by gating on NK cells (CD45+CD138−CD3− CD56+). (a) Representative 
histograms are shown. (B) Values reported represent the MFI values of NKG2D or DNAM-1 subtracted from the MFI value of the isotypic cIg or the percentage of 
NKG2D and DNAM-1. Total number of patients analyzed, n = 40 (Val/Val = 19, Val/Met n = 13, Met/Met = 8). Abbreviations: Val, valine; Met, methionine.
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corresponding to residues 152 to 161, essential for NKG2D 
recognition (27) (Figure 6A). Interestingly, the crystal structure 
of MICA in complex with NKG2D revealed that these nine 
MICA residues, which link the helices α2–1 and α2–2, are ordered 
upon binding to NKG2D (Figure 6B). The crystal structures also 
revealed that residue Met129 is localized at the end of the small 
β8-strand, far away from the MICA/NKG2D interface. This resi-
due forms, together with Trp127, Phe110, Phe117, and Leu118, a 
hydrophobic base on which the helix α2–1 docks (Figure 6C). The 
importance of such hydrophobic nucleus for the correct folding 
and orientation of a helix has been previously demonstrated (28). 
The hydrophobic residues Leu138, Ala139, Met140, and Val142 
FigUre 5 | Soluble MICA levels in the serum of multiple myeloma (MM) patients carrying the Val allele do not correlate with change in NKG2D expression.  
Peripheral blood derived from healthy donors were incubated for 16 h with medium alone or serum derived from MGUS or MM patients at different disease states 
carrying at least one Val allele and containing variable levels of soluble MICA. Cells were harvested and NKG2D expression was evaluated by gating on CD3−CD56+ 
natural killer (NK) cells. (a) A representative experiment is shown. (B) Values reported on y axis represent the MFI value of NKG2D subtracted from  
the MFI value of the isotypic cIg (high panel) or the percentage of NKG2D positive cells (lower panel) and were correlated with soluble MICA levels of each patient  
as indicated on x axis. Total number of serum patients analyzed, n = 16 (3 MGUS, 6 smoldering, 6 onset, 1 relapse).
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on the α2–1 helix face and interact with the β-sheet docking site 
described above (Figure 6C). The large and hydrophobic residue 
Met129 is at the heart of this putative nucleating site, forming van 
der Waals interactions with residues Gln136, Ala139, and Met140 
all localized on the α2–1 helix (Figure 6C).
The clear differences in binding affinity between the two MICA 
variants and NKG2D have been previously suggested to be due to 
conformational changes (5). However, this is in our opinion unlike 
since comparison of the crystal structure of MICB (30) which 
comprises a Val residue at position 129, with the crystal structure 
of MICA-129Met, reveals the similarity of their conformations 
(Figure 6D). Instead, molecular modeling analysis indicated that 
replacement of residue Met129 with the much smaller Val residue 
removes at least three van der Waals interactions between the α2–1 
helix and the β-sheet on which it docks, and generates a solvent 
accessible cavity in this hydrophobic core. Furthermore, com-
parative analysis of the two crystal structures of MICA indicates 
that the α2–1 helix rotates slightly upon NKG2D binding around 
the contact between Met129 and Ala139, resulting in significant 
movements at both ends of this helix (Figure 6E). Mutation of 
residue Met129, which we believe acts a lever stop for the helix 
α2–1 to build the conformation optimal for the NKG2D binding, 
would clearly have a significant impact on the direction and tilt-
ing of the helix. Thus, the Met to Val dimorphism could affect 
FigUre 6 | Residue Met129 is essential for appropriate positioning of the α2–1 helix for NKG2D recognition. (a) The crystal structure of the free form of MICA is 
colored according to its secondary structure, with helices, β-strands and loops in red, yellow, and green, respectively. Only the α1 and α2 regions of MICA are 
displayed. The region comprising residues 152–161 and which is not visible in the electron density due to disorder, is indicated by a dashed line. All atoms forming 
residue Met129 are indicated as balls with oxygen, nitrogen, sulfur, and carbon atoms colored in red, blue, orange, and yellow, respectively. (B) The crystal structure  
of the MICA/NKG2D complex reveals that the flexible 152–161 region (in blue) is stabilized through interactions with NKG2D. The two subunits of NKG2D receptor 
are displayed in green and cyan. Residue Met129 is localized far away from the MICA/NKG2D interface. (c) Residue Met129 plays a key role within a hydrophobic 
core formed between helix α2–1 and several β-sheet residues that surround and interact with Met129. The van der Waals interactions formed between Met129 and 
residues (in red) on the helix α2–1 are indicated by green dashed lines. (D) Superposition of the α1α2 domains of MICA and MICB, in pink and cyan, respectively, 
reveals that Met129 in MICA and Val129 in MICB take the same position and orientation, and demonstrates that MICA-129Met/Val dimorphism does not affect the 
conformation of the two MIC alleles (29). (e) The MICA α2–1 helix rotates following complex formation with NKG2D. Both ends of free MICA (red) are deviating  
from their position in the complex with NKG2D (orange), by 1.5 and 2.0 Å at the N- and C-termini, respectively.
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the MICA transition from disorder to form an optimal template 
for NKG2D recognition, providing a reasonable, although still 
hypothetical, explanation for the difference in the binding capac-
ity of the two MICA variants to NKG2D.
DiscUssiOn
In this study, we investigated the association of MICA genetic 
polymorphisms and sera levels with the progression of MM. 
Interestingly, our findings indicate that the MICA-129Met/Val 
dimorphism is associated with: (i) differential expression of both 
soluble and cell surface MICA, (ii) expression levels of NKG2D 
on ex vivo NK cells isolated from the BM and PBL of MM patients, 
and (iii) the disease state.
Polymorphisms of MICA have been largely investigated 
for their role in infections, autoimmune diseases, and cancer 
(31). Due to its functional consequences, a number of disease 
association studies with the MICA-129 dimorphism have been 
previously performed (32). Interestingly, we found an higher 
frequency of relapse in MM patients carrying the MICA-129Val/
Val genotype that was also observed by analyzing the patients 
outcome in response to the therapy.
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Other studies in different cancer models have reported that the 
MICA-129Val/Val genotype can be associated with higher risk 
for nasopharyngeal (NC) and breast cancer (33, 34). Increasing 
evidence has pointed out a key role for the NKG2D activating 
receptor and its ligands in the surveillance of MM. In particular 
Rebmann and coworkers have shown that soluble MICA levels 
correlate with tumor progression, and this molecule has been 
proposed as a prognostic marker in MM (19). Our findings dem-
onstrate that increased levels of soluble MICA can be found in 
MM patients sera during the progression from MGUS to relapse 
and clearly show for the first time that the presence of soluble 
MICA is associated with the MICA-129Val allele. As matter of 
fact, in other pathological conditions, including Ulcerative Colitis 
and Hepatitis B infection (35, 36), the MICA-129Val/Val genotype 
has been associated with the highest soluble MICA serum levels.
In line with our in vivo results showing both a higher expres-
sion of cell surface and soluble MICA in MICA-129Val/Val 
patients, Isernhagen and colleagues reported that soluble MICA 
levels as well as its cell-surface expression were higher in a panel 
of tumor and melanoma cell lines carrying the MICA-129Val/Val 
genotype (21). It is possible that the MICA-129Val allele has a 
higher transcriptional activity which might explain its effect on 
soluble and cell-surface MICA levels (37). Another non-excluding 
possibility is that the higher amount of soluble MICA-129Val 
could be directly due to the 30-times lower affinity of this variant 
to NKG2D compared to MICA-129Met resulting in a reduced 
transfer to NK cells and its accumulation on the surface of MM 
target cells.
Previous studies suggested that elevated levels of soluble 
MICA in the sera of cancer patients correlate with an increased 
NKG2D downregulation on PBL NK  cells and T  lymphocytes 
(22). However, it is still unclear whether soluble MICA has the 
capability to directly induce NKG2D downregulation and/or if 
additional soluble factors in the sera of cancer patients contri-
bute to this effect. Infact, Paschen and coworkers demonstrated 
that elevated levels of soluble NKG2D ligands (i.e., MICA and 
ULBP2) in the sera of melanoma patients were not associated 
with a significant downregulation of NKG2D expression on 
peripheral NK cells (38). Even NK cells from rheumatoid arthritis 
patients with relatively high soluble MICA levels, did not show 
diminished NKG2D expression (39). Furthermore in MM, solu-
ble MICA was not significantly associated with NKG2D down-
regulation and in  vitro experiments with MM patients’ serum 
and culture supernatants, did not result in changes in NKG2D 
expression (40). Similarly, by incubating NK cells with sera from 
patients containing different amounts of soluble MICA, we did 
not find a significant correlation between the levels of soluble 
MICA and the extent of NKG2D downmodulation. Interestingly, 
we observed that the lowest levels of NKG2D on NK cells from 
MM patients, were associated with the MICA-129Met/Met 
genotype. In line with these findings, it has been shown that the 
MICA-129Met  allele, with proven higher affinity to NKG2D, is 
able to induce significantly stronger downmodulation of NKG2D 
in both NK and CD8 T  lymphocytes, and to better stimulate 
IFNγ production as compared to the MICA-129Val allele (6). 
It should be considered that receptor endocytosis not only leads 
to reduced cell-surface receptor abundance but also controls 
signaling outcome in NK cells as shown by Molfetta and cow-
orkers who reported that ubiquitin-dependent NKG2D/DAP10 
endocytosis was required for the activation of extracellular signal-
regulated kinase and NK cell functions (41, 42). It is possible that 
cancer cells carrying the MICA-129Met allele could better induce 
NK  cell activation that corresponded to a substantial NKG2D 
reduction observed in patients. By performing in vitro degranula-
tion assays on NKG2D-sensitive targets, “ex vivo” unstimulated 
NK cells derived from patients had very low levels (below 5%) 
of degranulation, independently of the MICA genotype (data 
not shown). This result is in accordance with previous evidences 
indicating that stimulation of NKG2D alone is not sufficient 
to trigger cytotoxicity and/or cytokine production in resting 
human NK cells (43). In fact, effector functions mediated by this 
receptor rely on different factors including the activation status 
of NK cells, the cooperation with other NK activating receptors 
or with distinct cytokines (44). Thus, in MM patients, the tumor 
microenvironment, the cytokine milieu and the expression of 
other NK cell activating ligands on cancer cells can dictate the 
final outcome of the NKG2D-mediated NK cell response.
Our results obtained by structural modeling analysis sug-
gested that the Met to Val dimorphism could affect the capacity 
of MICA to form an optimal template for NKG2D recognition. 
It is possible that the lowest NKG2D levels in MM patients 
with a MICA-129Met/Met genotype reflects the capacity of the 
MICA-129Met allele to more efficiently engage NKG2D and trig-
ger NK cell activity in a cell–cell contact manner and this event 
appears to be independent from soluble MICA sera levels that are 
instead predominant in individuals carrying the MICA-129Val 
allele.
In conclusion, our data indicate that the MICA-129Val allele is 
associated with significantly higher levels of soluble MICA and an 
higher frequency of relapse and strongly suggest that the MICA 
genotype could be used as prognostic marker in alternative to 
soluble MICA if further data with higher numeric dimension will 
confirm these findings. Altogether, these observations could help 
to develop more personalized predictive biomarkers in MM.
MaTerials anD MeThODs
clinical samples
Sera, PBMCs, and BM samples were obtained from MM patients 
enrolled at the Division of Hematology (Sapienza University of 
Rome). Informed and written consent in accordance with the 
Declaration of Helsinki was obtained from all patients, and 
approval was obtained from the Ethics Committee of the Sapienza 
University of Rome (Rif. 3373). Patients were classi fied according 
to the disease state. Patients (Onset and Relapse) were treated 
according to standard therapeutic protocols inclu d ing the usage 
of VMP (Bortezomib, Melphalan, Prednisone), VD (Bortezomib, 
Dexamethasone), and RD (Lenalidomide, Dexa methasone).
Mica gene Typing
For the genotyping of MICA, genomic DNA derived from patients 
PBMCs was isolated from 1 × 106 cells using the Genomic DNA 
purification kit according to the manufacturer’s instructions 
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(Bioline, London, UK). Sequence-based typing of MICA was 
performed as described before (45). The sequence of a new MICA 
allele was identified and the name MICA*085 has been officially 
assigned by the WHO Nomenclature Committee for factors of the 
HLA System in February 2015 (Genbank accession: KP262025).
immunofluorescence and Facs analysis
Analysis of MICA expression on patient-derived PCs was 
performed by gating the CD38+CD138+ PC population using 
the antibodies anti-MICA (clone 159227, R&D Systems, 
Minneapolis, MN, USA), anti-CD38/APC, and anti-CD138/
FITC (both from BD Bioscience, San Jose, CA, USA) as previ-
ously reported (16); samples were acquired using a FACSCanto 
(BD Biosciences, San Jose, CA, USA) and a FACSCalibur (Becton 
Dickinson). Analysis of NKG2D and DNAM-1 on NK cells from 
PBMCs or BM aspirates was performed by gating on the CD45+
CD138−CD3−CD56+ population using the antibodies anti-CD3/
allophycocyanin-H7, anti-CD56/PE, anti-CD138/FITC, anti-
CD45/PE-Cy7, anti-NKG2D/APC, or anti-DNAM-1/APC (BD 
Bioscience). In some experiments, anti-CD16/PerCP mAb was 
also used (BD Bioscience). In the experiments relative to Figure 4 
and Figure S2 in Supplementary Material, all the patients-derived 
samples were acquired using a FACSCanto (BD Biosciences, San 
Jose, CA, USA). In the experiments relative to Figure 5, PBMCs 
derived from healthy donors were incubated with medium alone 
or serum derived from MGUS or MM patients for 16 h. After har-
vesting, cells were stained with antibodies from BD Bioscience: 
anti-CD3/PerCP, anti-CD56/APC, and anti-NKG2D/PE; samples 
were acquired using a FACSCalibur (Becton Dickinson).
Data analysis was performed using the FlowJo 9.3.2 program 
(TreeStar, Ashland, OR, USA).
enzyme-linked immunosorbent  
assay (elisa)
Enzyme-linked immunosorbent assays for soluble MICA, 
MICB, and ULBP1 were from R&D Systems (Minneapolis, MN, 
USA), and performed as previously described (46), with modifi-
cations (AMO1 anti-MICA capture mAb, 2 µg/ml, BAMOMAB, 
Germany) (47). Soluble ULBP2 was detected as previously des-
cribed (15). Absorbance values of triplicate samples were obtained 
by subtracting readings at 540 nm from readings at 450 nm. Net 
absorbance was obtained by subtracting the reagent blank absorb-
ance. Before the assay, sera samples were diluted in PBS/0.1% 
Triton X-100 (vol/vol) and incubated for 30 min at 37 C.
Molecular Modeling of the Mica-Val129 
Variant and structural analysis
In order to evaluate the structural consequences of the MICA 
polymorphism, we created a three-dimensional molecular model 
of the MICA-Val129 variant, using the crystal structures of the 
free MICA-Met129 molecule (PDB code 1B3J) and the MICA- 
Met129/NKG2D complex (PDB code 1HYR) (26, 27) as templates. 
The creation of the molecular model of the MICA-Val129 variant, 
as well as all comparative structural analyses, was performed 
using the program Coot (48). Figure  5 was created using the 
program PyMol (PyMol Molecular Graphics System, Version 
1.5.0.4 Schrödinger, LLC).
statistic
In all the experiments, statistic was performed using the unpaired 
Mann–Whitney test, except for Figure 1D in which the unpaired 
t-test with Welch’s correction was used. *<0.05; **<0.01; 
***<0.001. χ2 test was used to analyze frequency data.
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obtained from the Ethics Committee of the Sapienza University 
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